Thiruvananthapuram: An Ayurvedic medicine developed by Pankajakasthuri Herbal Research Foundation in Kerala has been approved for a clinical trial on COVID-19 patients by the Clinical Trial Registry of India (CTRI). “Zingivir-H tablet, which is effective against respiratory infections, viral fever, acute viral bronchitis, has been found to be effective against the Respiratory Syncytial Virus and Influenza virus during scientific validation.
In vitro experiments done at the Rajiv Gandhi Center for Biotechnology have proven that there are no side effects in the human cell,” Dr J Hareendran Nair, Founder, Pankajakasthuri Herbal Research Foundation told ANI.
He said that after the study he approached medical colleges in Tamil Nadu, Karnataka, Maharashtra, Telangana and Delhi. “I approached medical colleges in Tamil Nadu, Karnataka, Maharashtra, Telangana and Delhi and some of them accepted my request and got institutional medical committee approval.
After that I approached CTRI for the approval and then the clinical trial started,” he said. “ZingiVir-H has seven ingredients including herbomineral and these have been prescribed in our scientific manuscript. It has been part of our clinical practice for so many years. I have been using this formula for nearly 15 years for viral fever, acute viral bronchitis and contagious fever and have got fantastic results,” Nair added.